Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $8.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $8.0 million, down 11.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.0 million (down 5.96% YoY), and the FY2025 annual result was $35.0 million, down 2.78% from the prior year.
• Depreciation & Amortization (CF) eased to $8.0 million in Q1 2026 per RARE's latest filing, from $8.8 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $9.5 million in Q4 2024 and troughed at $4.1 million in Q1 2022.
• A 5-year average of $7.2 million and a median of $8.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) jumped 68.93% in 2024, then decreased 11.11% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $5.0 million in 2022, then jumped by 65.66% to $8.2 million in 2023, then increased by 16.12% to $9.5 million in 2024, then dropped by 7.88% to $8.8 million in 2025, then fell by 8.94% to $8.0 million in 2026.
• Business Quant data shows RARE's Depreciation & Amortization (CF) at $8.0 million in Q1 2026, $8.8 million in Q4 2025, and $8.6 million in Q3 2025.